Sanofi opens a new chapter in Tunisia by formalizing a strategic partnership with the Kilani Group, one of the major health players in the country. Behind this agreement, a notable evolution of the French multinational’s operating model: the stated objective is to sustain access to care, to secure the availability of treatments, and to strengthen local industrial anchoring, in a regional context where more and more “Big Pharma” companies are favoring national alliances rather than direct presence.
Concretely, the partnership rests on a “dual” organization within the Kilani Group, mobilizing two complementary subsidiaries to cover the entire value chain of Sanofi’s activities on the local market. On one side, Teriak will take charge of production in Tunisia of a significant portion of Sanofi’s drug portfolio. On the other, MEDICIS S.A.R.L will inherit the strategically important aspect: medical information, relations with health authorities and scientific promotion among health professionals.
This distribution of roles aims at a priority objective: to avoid any disruption of the supply chain and to guarantee the continuity of access to treatments, especially those deemed essential. The logic is twofold. For Sanofi, it is about gaining agility and better aligning with national health priorities. For Kilani Group, it is the recognition of an industrial, logistical, and scientific capability allowing it to carry complex portfolios and operate to international standards.
In the statements accompanying the announcement, Sara Masmoudi highlights a “recognition” of the group’s expertise and a commitment to Tunisian public health. Sanofi, for its part, through Rami Mroueh, describes this partnership as a “new chapter”: the alliance with a leading local player should enable faster responses to market needs and support the introduction of therapeutic innovations, in line with the health authorities’ directions.
The industrial and human weight of Kilani Group is at the heart of the equation: the company claims 2,900 employees and a presence across the entire pharmaceutical chain, from production to importation, including distribution and medical promotion. The agreement with Sanofi thus strengthens its position in the Tunisian industry, while projecting a broader ambition: to contribute to strengthening Tunisia’s health sovereignty through local industrialization and the securing of supply chains.
Beyond the Sanofi–Kilani case, this turn illustrates a structural trend in the MENA region: pharmaceutical multinationals are turning toward local industrial and commercial alliances capable of meeting quality requirements, regulatory compliance, and continuity of access. By leveraging national infrastructure, Sanofi can preserve its footprint and market shares, while aligning with the public policy logic of “health sovereignty” that is gaining ground in the region.
What this partnership actually changes for the Tunisian sector
On paper, the immediate advantage is clear: greater proximity and greater resilience. Locally producing a portion of the portfolio reduces dependence on international fluctuations (logistics, delays, supply tensions) and can limit disruption risks, a matter particularly sensitive for patients as well as health professionals. The transfer of activity to a Tunisian manufacturer with international standards also strengthens the credibility of the pharmaceutical “Made in Tunisia,” with a potential ripple effect: skills development, investments, higher quality requirements, and the consolidation of a subcontracting network.
But the balance will depend on several conditions. First, the execution capacity: maintaining constant levels of quality and compliance, absorbing the complexity of a multinational portfolio, and perfectly synchronizing production, distribution, and medical information. Next, the continuity governance: a model based on a strong local partner can secure… but it also concentrates operational risk if a link is weakened (raw material shortages, financial constraints, industrial incidents).
Finally, the most strategic challenge remains innovation: the promise to introduce new therapeutic solutions will depend on regulatory fluidity, market launch capacity, reimbursement policies, and, more broadly, the attractiveness of the Tunisian market for innovations.
For Tunisia, this partnership could become a signal: that a country capable of hosting more advanced models of cooperation between Big Pharma and national players, provided that this announcement is transformed into concrete results on the ground — availability, quality, accessibility, and rising industrial value.
